What is the efficacy of chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma?

Updated: May 04, 2018
  • Author: Sameh Gaballa, MD, MS; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

CAR T-cells that target B-cell maturation antigen (BCMA) on multiple myeloma cells have entered early clinical trials. A Chinese trial reported durable responses in 33 of 35 patients, including stringent complete responses in 14 patients. Similar results have been reported in 27% of heavily pretreated patients with multiple myeloma in a United States phase I trial. [16]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!